What Is Frag 176-191?
Frag 176-191 — also known in research literature as AOD-9604, hGH Frag 176-191, or tyr-hGH 177-191 — is a synthetic peptide derived from the C-terminal end of the human growth hormone (hGH) molecule. It comprises the last 16 amino acids of hGH — a region researchers have hypothesized to be the molecule’s primary lipolytic segment, thought to be associated with promoting the breakdown of adipose tissue and mobilizing lipids from fat cells in laboratory models.
To support peptide stability, tyrosine replaces the first amino acid in its sequence — a modification that gives rise to the alternative designation tyr-hGH 177-191. Researchers believe this structural change may increase Frag 176-191’s resistance to enzymatic degradation, with the endogenously occurring disulfide bridge between cysteine residues in the peptide structure thought to further contribute to its structural integrity — and possibly to its persistence in challenging laboratory environments including the gastrointestinal tract.
Researchers have historically drawn parallels between this fat metabolism peptide and hGH’s proposed catabolic interactions with adipose tissue stores — while also noting that Frag 176-191 appears to offer a more targeted research tool, given its proposed selectivity for fat metabolism-related pathways without the broader hormonal interactions associated with the full hGH molecule.
Frag 176-191 and Adipocyte Function
At the core of Frag 176-191 research is its proposed interaction with adipocyte — or fat cell — biology in laboratory models. Researchers have hypothesized that this fat metabolism peptide may influence adipocyte metabolism through multiple molecular pathways, potentially including the upregulation of beta-3 adrenergic receptors (β3-AR) — receptors thought to play a key role in promoting lipolysis and thermogenesis in laboratory settings.
Preliminary research suggests that Frag 176-191 may support the transcriptional activity of β3-AR genes — potentially contributing to increased mRNA expression and subsequent protein synthesis in adipocyte models. Elevated receptor density on adipocyte membranes may theoretically heighten cellular sensitivity to endogenous catecholamines such as adrenaline, which are thought to engage β3-AR and promote fat breakdown in laboratory settings.
In experimental studies involving murine models with excess adipose tissue stores, exposure to Frag 176-191 over two weeks appeared to correlate with reductions in model mass and tentative evidence of increased β3-AR RNA expression — suggesting a possible modulation of beta-adrenergic signaling pathways in these laboratory models. Interestingly, even in murine models with impaired lipolytic receptors, researchers observed reductions in adipose tissue stores — implying that Frag 176-191’s mechanisms may extend beyond direct receptor activation, potentially involving alternative pathways related to energy expenditure and fat oxidation. These remain speculative and warrant further investigation in laboratory settings.
A notable laboratory study — METAOD005 — explored these possibilities across 300 research models divided into six groups over a 12-week evaluation period. Results indicated that one of the Frag 176-191-exposed groups experienced a potential average reduction in mass of approximately 5.7 pounds compared to controls. Researchers also suggested possible improvements in lipid profiles and glucose tolerance among exposed models — though these findings remain tentative and pending further verification in laboratory settings.
Frag 176-191 and Glycogen Metabolism
Beyond adipocyte biology, Frag 176-191 has also been studied for its potential interactions with glycogen metabolism in laboratory models — a research area that adds an important dimension to this fat metabolism peptide’s broader cellular research profile.
Research examining synthetic hGH peptides — including Frag 176-191 (also referred to as Frag 176-191 in earlier literature) — investigated potential interactions with glycogen metabolism in murine models with normal physiological function. Following peptide exposure, researchers observed a modest increase in blood glucose and lactate levels, alongside a reduction in the active-to-inactive ratio of glycogen synthase in muscular tissue, adipose tissue, and liver samples — while total glycogen synthase concentrations remained unchanged.
Researchers proposed that these findings suggest Frag 176-191 may influence glucose homeostasis by shifting glycogen synthase toward its inactive form in laboratory models — potentially suppressing glycogen synthesis while supporting glycogenolysis and contributing to elevated circulating glucose and lactate levels. The researchers described this as consistent with a modified Cori Cycle mechanism — in which lactate production and gluconeogenic flux appear to interact with glycogen synthase inactivation to produce the observed glycemic changes in these laboratory models. While mechanistically interesting, researchers have been careful to note that further investigation is needed to fully characterize the implications of these glycogen-related interactions.
Frag 176-191 and Cartilage Regeneration
One of the more surprising and actively investigated areas of Frag 176-191 research involves its potential interactions with cartilage tissue in laboratory models — an area that has drawn considerable interest given the peptide’s proposed regenerative properties beyond its fat metabolism research profile.
Preliminary research explored this potential using a collagenase-induced knee osteoarthritis model — a standard laboratory approach for studying cartilage damage and repair. Research models were divided into four groups following cartilage damage induction: a saline control group, a hyaluronic acid group, an Frag 176-191 group, and a combination group receiving both Frag 176-191 and hyaluronic acid together.
Cartilage regeneration was assessed through morphological and histopathological analyses over a 4–8 week evaluation period. Results indicated significantly higher cartilage damage scores in the control group compared to all treatment groups. Notably, the combination group — receiving both Frag 176-191 and hyaluronic acid — exhibited the lowest damage scores and significantly reduced lameness duration compared to all other groups. Researchers concluded that Frag 176-191 exposure appeared to enhance cartilage regeneration in these laboratory models, with the combined approach appearing more effective than either compound alone — a finding that has added a regenerative tissue research dimension to this fat metabolism peptide’s expanding laboratory research profile.
References
- Cox HD, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31–8.
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001;142(12):5182–9.
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7–15.
- Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64–77.
- Valentino MA, et al. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharmacol Ther. 2010;87(6):652–62.
- Ma GY, et al. The mechanism of the hyperglycaemic action of synthetic peptides related to the C-terminal sequence of human growth hormone. Biochim Biophys Acta. 1982;716(3):400–9.
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426–32.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
